Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [11C]SMW139 and [18F]F-DPA.

IF 3.1 3区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Obada M Alzghool, Richard Aarnio, Jatta S Helin, Saara Wahlroos, Thomas Keller, Markus Matilainen, Junel Solis, Jonathan J Danon, Michael Kassiou, Anniina Snellman, Olof Solin, Juha O Rinne, Merja Haaparanta-Solin
{"title":"Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [<sup>11</sup>C]SMW139 and [<sup>18</sup>F]F-DPA.","authors":"Obada M Alzghool, Richard Aarnio, Jatta S Helin, Saara Wahlroos, Thomas Keller, Markus Matilainen, Junel Solis, Jonathan J Danon, Michael Kassiou, Anniina Snellman, Olof Solin, Juha O Rinne, Merja Haaparanta-Solin","doi":"10.1186/s13550-024-01085-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>P2X7 receptor has emerged as a potentially superior PET imaging marker to TSPO, the gold standard for imaging glial reactivity. [<sup>11</sup>C]SMW139 is the most recently developed radiotracer to image P2X7 receptor. The aim of this study was to image reactive glia in the APP/PS1-21 transgenic (TG) mouse model of Aβ deposition longitudinally using [<sup>11</sup>C]SMW139 targeting P2X7 receptor and to compare tracer uptake to that of [<sup>18</sup>F]F-DPA targeting TSPO at the final imaging time point. TG and wild type (WT) mice underwent longitudinal in vivo PET imaging using [<sup>11</sup>C]SMW139 at 5, 8, 11, and 14 months, followed by [<sup>18</sup>F]F-DPA PET scan only at 14 months. In vivo imaging results were verified by ex vivo brain autoradiography, immunohistochemical staining, and analysis of [<sup>11</sup>C]SMW139 unmetabolized fraction in TG and WT mice.</p><p><strong>Results: </strong>Longitudinal change in [<sup>11</sup>C]SMW139 standardized uptake values (SUVs) showed no statistically significant increase in the neocortex and hippocampus of TG or WT mice, which was consistent with findings from ex vivo brain autoradiography. Significantly higher [<sup>18</sup>F]F-DPA SUVs were observed in brain regions of TG compared to WT mice. Quantified P2X7-positive staining in the cortex and thalamus of TG mice showed a minor increase in receptor expression with ageing, while TSPO-positive staining in the same regions showed a more robust increase in expression in TG mice as they aged. [<sup>11</sup>C]SMW139 was rapidly metabolized in mice, with 33% of unmetabolized fraction in plasma and 29% in brain homogenates 30 min after injection.</p><p><strong>Conclusions: </strong>[<sup>11</sup>C]SMW139, which has a lower affinity for the rodent P2X7 receptor than the human version of the receptor, was unable to image the low expression of P2X7 receptor in the APP/PS1-21 mouse model. Additionally, the rapid metabolism of [<sup>11</sup>C]SMW139 in mice and the presence of several brain-penetrating radiometabolites significantly impacted the analysis of in vivo PET signal of the tracer. Finally, [<sup>18</sup>F]F-DPA targeting TSPO was more suitable for imaging reactive glia and neuroinflammatory processes in the APP/PS1-21 mouse model, based on the findings presented in this study and previous studies with this mouse model.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"25"},"PeriodicalIF":3.1000,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10917722/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-024-01085-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Background: P2X7 receptor has emerged as a potentially superior PET imaging marker to TSPO, the gold standard for imaging glial reactivity. [11C]SMW139 is the most recently developed radiotracer to image P2X7 receptor. The aim of this study was to image reactive glia in the APP/PS1-21 transgenic (TG) mouse model of Aβ deposition longitudinally using [11C]SMW139 targeting P2X7 receptor and to compare tracer uptake to that of [18F]F-DPA targeting TSPO at the final imaging time point. TG and wild type (WT) mice underwent longitudinal in vivo PET imaging using [11C]SMW139 at 5, 8, 11, and 14 months, followed by [18F]F-DPA PET scan only at 14 months. In vivo imaging results were verified by ex vivo brain autoradiography, immunohistochemical staining, and analysis of [11C]SMW139 unmetabolized fraction in TG and WT mice.

Results: Longitudinal change in [11C]SMW139 standardized uptake values (SUVs) showed no statistically significant increase in the neocortex and hippocampus of TG or WT mice, which was consistent with findings from ex vivo brain autoradiography. Significantly higher [18F]F-DPA SUVs were observed in brain regions of TG compared to WT mice. Quantified P2X7-positive staining in the cortex and thalamus of TG mice showed a minor increase in receptor expression with ageing, while TSPO-positive staining in the same regions showed a more robust increase in expression in TG mice as they aged. [11C]SMW139 was rapidly metabolized in mice, with 33% of unmetabolized fraction in plasma and 29% in brain homogenates 30 min after injection.

Conclusions: [11C]SMW139, which has a lower affinity for the rodent P2X7 receptor than the human version of the receptor, was unable to image the low expression of P2X7 receptor in the APP/PS1-21 mouse model. Additionally, the rapid metabolism of [11C]SMW139 in mice and the presence of several brain-penetrating radiometabolites significantly impacted the analysis of in vivo PET signal of the tracer. Finally, [18F]F-DPA targeting TSPO was more suitable for imaging reactive glia and neuroinflammatory processes in the APP/PS1-21 mouse model, based on the findings presented in this study and previous studies with this mouse model.

使用[11C]SMW139和[18F]F-DPA对P2X7受体和TSPO进行PET成像,评估β-淀粉样蛋白沉积小鼠模型的神经胶质反应性。
背景:P2X7 受体已成为一种潜在的 PET 成像标记,优于胶质反应性成像的黄金标准 TSPO。[11C]SMW139是最近开发的用于成像P2X7受体的放射性示踪剂。本研究的目的是使用针对P2X7受体的[11C]SMW139对APP/PS1-21转基因(TG)小鼠Aβ沉积模型中的反应性神经胶质进行纵向成像,并将示踪剂摄取量与针对TSPO的[18F]F-DPA在最后成像时间点的摄取量进行比较。TG小鼠和野生型(WT)小鼠分别在5、8、11和14个月时接受了[11C]SMW139的纵向体内PET成像,之后仅在14个月时接受了[18F]F-DPA PET扫描。体内成像结果通过体外脑部自显影、免疫组化染色以及对TG和WT小鼠体内[11C]SMW139未代谢部分的分析进行了验证:结果:[11C]SMW139 标准摄取值(SUVs)的纵向变化显示,TG 或 WT 小鼠的新皮质和海马中的[11C]SMW139 标准摄取值没有统计学意义上的显著增加,这与体内外脑自显影的结果一致。与 WT 小鼠相比,TG 小鼠脑区的[18F]F-DPA SUV 明显更高。TG小鼠大脑皮层和丘脑中的P2X7阳性定量染色显示,随着年龄的增长,受体的表达量略有增加,而TSPO阳性染色则显示,随着年龄的增长,TG小鼠在相同区域的表达量增加得更厉害。[11C]SMW139在小鼠体内迅速代谢,注射 30 分钟后,血浆中未代谢部分占 33%,脑匀浆中占 29%:结论:[11C]SMW139 对啮齿类 P2X7 受体的亲和力低于人类 P2X7 受体,无法成像 APP/PS1-21 小鼠模型中 P2X7 受体的低表达。此外,[11C]SMW139 在小鼠体内的快速代谢和几种脑穿透性放射性代谢物的存在极大地影响了该示踪剂的体内 PET 信号分析。最后,根据本研究和以前对APP/PS1-21小鼠模型的研究结果,以TSPO为靶点的[18F]F-DPA更适合成像APP/PS1-21小鼠模型中的反应性神经胶质和神经炎症过程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
EJNMMI Research
EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-
CiteScore
5.90
自引率
3.10%
发文量
72
审稿时长
13 weeks
期刊介绍: EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信